Pharming products

Diirrenberger M, Werani J. The control of granulation process by Power consumption measurement in Pharm. Production in Proceedings 4th International Symposium on Agglomeration, Toronto, June 2-5, C.E. Capes Editor, Iron and Steel Soc. Inc., 1985 489 96. 

Wertheimer, A. Navarro, R. Managed Care Pharmacy Principles and Practice, Pharm Products Press Binghamton, New York, 1999 Vol. 232. 

Pharming Products, http // www.pharming.com/index.php act=prod 2004. 

Hussain AS, Yu X, Johnson RD. Application of neural computing in pharmaceutical product development. Pharm Res 1991 8 1248-52. 

Baird R.M. (1985) Microbial contamination of non-sterile pharmaceutical products made in hospitals in the North East Regional Health Authority. J Clin Hasp Pharm, 10, 95-100. 

KONG A N, YU R, CHEN c, MANDLEKAR s and PRIMIANO T (2000) Signal transduction events elicited by natural products role of M APK and caspase pathways in homeostatic response and induction of apoptosis . Arch Pharm Res, 23 1-16. 

Wang, Y.J. et al., Stability of curcumin in buffer solutions and characterization of its degradation products, J. Pharm. Biomed. Anal, 15, 1867, 1997. 

Cannabinidiol (CBND, 2.18) and cannabinol (2.19) are oxidation products of CBD and A9-THC formed by aromatization of the terpenoid ring. For the dehydrogenation of THC a radical mechanism including polyhydroxylated intermediates is suggested [10,11]. CBN is not the sole oxidation product of A9-THC. Our own studies at THC-Pharm on the stability of A9-THC have shown that only about 15% of lost A9-THC is recovered as CBN. 

Amidon, G. L., Lennemas, H., Shah, V. P., Crison, J. R. A. A theoretical basis for a biopharmaceutic drug classification the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413 20. 

Lazar, M. S., PhRMA guidelines for the production, packing, repacking, or holding of drug substances, Part I, Pharm. Technol., 19, 22, 1995. 

RK Chang, C Hsiao, JR Robinson. A review of aqueous coating techniques and preliminary data on release from a theophylline product. Pharm Technol ll(3) 56-68, 1987. 

KS Murthy, NA Enders, MB Fawzi. Dissolution stability of hard-shell products. Part I the effect of exaggerated storage conditions. Pharm Technol 13(3) 72-86, 1989. 

JB Schwartz. The instrumented tablet press uses in research and production. Pharm Tech 5(9) 102-132, 1981. 

B Jones. Two-piece gelatin capsules excipients for powder products, European practice. Pharm Tech Eur 7(10) 25-34, 1995. 

I Ullah, GJ Wiley, SN Agharkar. Analysis and simulation of capsule dissolution problem encountered during product scale-up. Drug Dev Ind Pharm 18 895-910, 1992. 

IR Berry. One-piece, soft gelatin capsules for pharmaceutical products. Pharm Eng 5(5) 15—19, 1985. 

K. Thai, G. C. Visor, J. Duffy, W. C. Hsu, and L. C. Foster, Stability of interleukin ip (IL-ip) in aqueous solution Analytical methods, kinetics, products and solution formulation implications, Pharm. Res, 8, 485 (1992). 

J. Brange, S. Havelund, and P. Hougaard, Chemical stability of insulin 2 Formation of higher molecular weight transformation products during storage of pharmaceutical preparations, Pharm. Res, 9, 727 (1992). 

D. E. Overcashier, T. W. Patapoff, and C. C. Hsu, Lyophilization of protein formulations in vials Investigation of the relationship between resistance to vapor flow during primary drying and small scale product collapse, J. Pharm. Sci., 88(7), 688 (1999). 

Heptinstall S, Awang DVS, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (1.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol 44 391-395, 1992. 

C. N. Swenson and G. Fundale, Observational cohort study of switching warfarin sodium products in a managed care organization, Am J. Health Syst. Pharm, 57, 452 (2000). 

---